Lv4
508 积分 2021-11-10 加入
Clinical Trial: Early Nivolumab Addition to Regorafenib in Patients With Hepatocellular Carcinoma in Second-Line (The GOING Trial)
28天前
已完结
TACE and tyrosine kinase inhibitors with or without PD-1 inhibitors as first-line therapy for intermediate-advanced HCC: a multicenter real-world cohort study
28天前
已完结
PERI-START: a phase II trial of perioperative TACE, tislelizumab, and lenvatinib in early-stage hepatocellular carcinoma
1个月前
已完结
Oncogenesis in cholangiocarcinoma
1个月前
已完结
Association between Complete Proteinuria Remission and Kidney Function in the Phase 3 PROTECT Trial of Sparsentan in IgA Nephropathy
2个月前
已关闭
Real-world efficacy of zanidatamab in patients with HER2 positive advanced biliary tract cancers
3个月前
已完结
An evaluation of zanidatamab, a novel, anti-HER2 biparatopic antibody, for the treatment of biliary tract cancer
4个月前
已完结
HER2-Targeted Therapies: Unraveling Their Role in Biliary Tract Cancers
4个月前
已完结
Efficacy and safety of radiotherapy versus transarterial chemoembolization in combination with lenvatinib and camrelizumab for hepatocellular carcinoma with inferior vena cava/right atrium tumor thrombus: a multicenter study
4个月前
已完结
Multicenter, retrospective GUIDANCE001 study comparing transarterial chemoembolization with or without tyrosine kinase and immune checkpoint inhibitors as conversion therapy to treat unresectable hepatocellular carcinoma: Survival benefit in intermediate or advanced, but not early, stages
5个月前
已完结
皖公网安备34019202002308
